| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/100-billion-pivot-why-johnson-johnson-my-top-dividend-king-buy-2026","as_of":"2026-04-11T16:37:43.480344+00:00","canonical_url":"https://www.fool.com/investing/2026/04/11/the-100-billion-pivot-why-johnson-johnson-is-my-to/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/100-billion-pivot-why-johnson-johnson-my-top-dividend-king-buy-2026","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_0c64d7370db03dfd","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/11/the-100-billion-pivot-why-johnson-johnson-is-my-to/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-11T22:29:13.821075+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsJohnson & Johnson is facing lawsuits, patent cliffs, and disruptive drug pricing negotiations.","fetched_title":"The $100 Billion Pivot: Why Johnson & Johnson Is My Top Dividend King to Buy in 2026 | Nasdaq","final_url":"https://www.nasdaq.com/articles/100-billion-pivot-why-johnson-johnson-my-top-dividend-king-buy-2026","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/100-billion-pivot-why-johnson-johnson-my-top-dividend-king-buy-2026","source_event_id":"evt_21bc56f0a5b2","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"8ee510fac7865303","kind":"unusual_volume","published_at":"2026-04-11T15:50:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2023","2024","2026","December 17, 2004"],"entities":[{"asset_class":"equity","name":"Johnson & Johnson","relevance":"primary focus","symbol":"JNJ","type":"company"},{"asset_class":"other","name":"S&P Global","relevance":"supports financial strength claim","symbol":"","type":"organization"},{"asset_class":"other","name":"Stelara","relevance":"example of patent cliff impact","symbol":"","type":"drug"},{"asset_class":"index","name":"Nasdaq Composite","relevance":"macro context mentioned","symbol":"^IXIC","type":"index"}],"event_type":"other","information_gaps":["The provided signal type is discovery_unusual_volume_delta, but the text contains no volume data (no baseline volume, no current volume, no volume ratio, and no direction).","No explicit statement confirms whether any unusual volume is confirmed by news; the article content provided does not mention trading volume changes or a specific catalyst tied to volume.","The most likely catalyst hypothesis for the volume spike cannot be grounded in the provided text because no volume anomaly details are given; only general investment thesis/catalysts (lawsuits, patent cliffs, pricing negotiations, revenue projection, dividend safety) are discussed."],"key_facts":["The article states Johnson & Johnson is dealing with thousands of lawsuits alleging talc-based products caused cancer.","The article states Johnson & Johnson lost patent exclusivity for Stelara in the U.S. in the prior year and that Stelara lost exclusivity in Europe in 2024.","The article states Stelara peak sales were $10.9 billion in 2023, accounting for almost 13% of Johnson & Johnson\u2019s top-line that year.","The article states Johnson & Johnson is facing government-imposed drug price negotiations in the U.S., which will reduce sales from targeted therapies.","The article states Johnson & Johnson\u2019s net sales grew 6% year over year to $94.2 billion last year.","The article states adjusted EPS rose 8.1% to $10.79 last year.","The article states Johnson & Johnson projects revenue will climb to about $100.5 billion at the midpoint in 2026 (6.7% year over year).","The article states Johnson & Johnson has an AAA rating from S&P Global.","The article states Johnson & Johnson has increased dividends for 63 consecutive years.","The article states the article\u2019s thesis is that healthcare demand and diversification plus financial position support the dividend even in a recession."],"numeric_claims":[{"label":"Net sales (last year)","value":"$94.2 billion"},{"label":"Net sales growth (YoY)","value":"6%"},{"label":"Adjusted EPS (last year)","value":"$10.79"},{"label":"Adjusted EPS growth (YoY)","value":"8.1%"},{"label":"Projected revenue midpoint (2026)","value":"$100.5 billion"},{"label":"Projected revenue growth (YoY, 2026 midpoint)","value":"6.7%"},{"label":"Stelara peak sales (2023)","value":"$10.9 billion"},{"label":"Stelara share of top-line (2023)","value":"~13%"},{"label":"Dividend increases (consecutive years)","value":"63"},{"label":"S&P Global credit rating","value":"AAA"}],"primary_claim":"Johnson & Johnson is projected to generate revenue of about $100.5 billion at the midpoint in 2026 despite ongoing lawsuits, patent cliffs, and U.S. drug price negotiations.","relevance_score":0.35,"sentiment":"mixed","source_quality":"high","summary":"The article argues that Johnson & Johnson (JNJ) remains a strong dividend stock despite lawsuits, patent expirations, and U.S. drug price negotiations, projecting revenue to exceed $100B in 2026. It frames the catalyst as resilience of diversified healthcare demand and financial strength supporting the dividend.","topics":["dividends","lawsuits","patent cliffs","drug pricing negotiations","revenue growth","healthcare demand resilience","financial credit rating"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsJohnson & Johnson is facing lawsuits, patent cliffs, and disruptive drug pricing negotiations.","tickers":[],"title":"The $100 Billion Pivot: Why Johnson & Johnson Is My Top Dividend King to Buy in 2026","url":"https://www.fool.com/investing/2026/04/11/the-100-billion-pivot-why-johnson-johnson-is-my-to/"}... |